Internal Reference Number: FOI_7679
Date Request Received: 17/01/2024 00:00:00
Date Request Replied To: 19/01/2024 00:00:00
This response was sent via: By Email
Request Summary: Request on intra-vitreal injections or implants
Request Category: Companies
| Question Number 1: I am analysing the usage of intra-vitreal injections or implants by the ¾¨Ó㴫ý. I would greatly appreciate if you could answer the following questions: How many of the following intra-vitreal injections/implants has your trust administered in the four-month period from September to December 2023: • Aflibercept • Bevacizumab - Avastin • Bevacizumab - Biosimilar • Brolucizumab • Dexamethasone • Faricimab • Fluocinolone acetonide • Ranibizumab - Lucentis (pre-filled syringes) • Ranibizumab - Lucentis (vials) • Ranibizumab – Ongavia | |
| Answer To Question 1: Aflibercept 1122 Bevacizumab – Avastin 6 Bevacizumab – Biosimilar 0 Brolucizamab 0 Dexamethasone 16 Faricimab 751 Fluocinolone acetonide 0 Ranibizumab - Lucentis (pre-filled syringes) <5 Ranibizumab - Lucentis (vials) 0 Ranibizumab – Ongavia 0 | |
| Question Number 2: Please see attached | |
| Answer To Question 2: See attached table. To accompany this answer to question 2 please also see the documents listed below:  7679 - Q2 Table Completed.docx | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
